Sponsor Directory

Pfizer clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3277

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Neoplasm Metastasis
Interventions: PF-07265807, Sasanlimab, Axitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more

Conditions: Cancer, Non-small Cell Lung Cancer (NSCLC)
Interventions: Cofetuzumab Pelidotin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Springdale, Arkansas • Stanford, California + 8 more

Conditions: Healthy Participants
Interventions: Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet Formulation, Single dose of PF-07220060 as a Tablet Formulation, Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration, Single dose of PF-07220060 as third tablet formulation; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Tumor
Interventions: PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more

Conditions: Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions: Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation; Drug · Procedure
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 19 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 11
States / cities: Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more

Conditions: Lyme Disease
Interventions: VLA15, Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 82
States / cities: Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more

Conditions: Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite, Fatigue, Cachexia
Interventions: ponsegromab, Placebo for ponsegromab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 19
States / cities: Conway, Arkansas • Little Rock, Arkansas • North Little Rock, Arkansas + 14 more

Conditions: Healthy
Interventions: [phenyl-14C]ARV-471, [oxoisoindolin-14C]ARV-471; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4,184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions: PF-07257876; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more

Conditions: Obesity and Obesity-related Medical Conditions
Interventions: MET233 and MET097, Placebo, MET097; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 381 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: COVID-19, SARS-COV-2 Infection
Interventions: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain); Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 12 Years and older
Enrollment: 774 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 19
States / cities: Walnut Creek, California • Milford, Connecticut • Washington D.C., District of Columbia + 13 more

About this Pfizer sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Pfizer is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pfizer trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Pfizer clinical trials

Filter and sort this sponsor

Live official records

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

PF-07284892 in Participants With Advanced Solid Tumors

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

About this Pfizer sponsor directory page